Testosterone Cypionate: History and Development

Early Testosterone Research: From Isolation to Injectable Esters

The story of testosterone cypionate begins with the isolation of testosterone itself. In 1935, Ernst Laqueur's group at the University of Amsterdam crystallized testosterone from bull testes, while Adolf Butenandt and Leopold Ružička independently achieved partial synthesis from cholesterol that same year. Ružička received the Nobel Prize in Chemistry (1939) for this work.

The Problem With Native Testosterone

Pure testosterone posed an immediate clinical problem. Injected in aqueous solution, it cleared the bloodstream within hours, making it impractical for sustained therapy. Oral testosterone underwent near-complete first-pass hepatic metabolism, producing dangerously hepatotoxic 17-alpha-alkylated metabolites in the formulations attempted at the time [1].

The Esterification Solution

Chemists solved the half-life problem through esterification. Attaching a carboxylic acid chain to the 17-beta hydroxyl group of testosterone created a prodrug that dissolved in oil and released active hormone slowly after intramuscular injection. Testosterone propionate, the first commercially successful ester, reached the market in 1937. It required injections every 2 to 3 days. Testosterone enanthate followed in the late 1940s with a longer chain, extending dosing intervals to 2 to 4 weeks.

Testosterone cypionate (testosterone cyclopentylpropionate) was synthesized by the Upjohn Company in 1951, adding a cyclopentane ring to the propionic acid side chain. This structural modification produced an ester with a slightly longer carbon chain than enanthate and a comparable pharmacokinetic profile, but with preferential adoption in U.S. Clinical practice [2].

FDA Approval and the Depo-Testosterone Era

Testosterone cypionate entered U.S. Clinical use in the 1950s under Upjohn's Depo-Testosterone brand. The FDA formally approved the current New Drug Application (NDA) in 1979, though the compound had been marketed under earlier regulatory frameworks for more than two decades prior.

Original Indications and Label Changes

The original FDA-approved indications included male hypogonadism (both primary testicular failure and hypogonadotropic forms), delayed puberty in adolescent males, and metastatic breast cancer in women. The breast cancer indication has since fallen out of use with the development of targeted hormonal therapies like aromatase inhibitors and selective estrogen receptor modulators.

Scheduling as a Controlled Substance

The Anabolic Steroids Control Act of 1990 classified testosterone cypionate and all anabolic steroids as Schedule III controlled substances under the Controlled Substances Act. This legislation was driven by widespread non-medical use among athletes and bodybuilders throughout the 1980s. Schedule III classification imposed prescribing restrictions, refill limits (five refills within six months), and record-keeping requirements that remain in effect today.

Generic Entry

Multiple generic manufacturers began producing testosterone cypionate after Upjohn's market exclusivity expired. By the early 2000s, generic 200 mg/mL formulations in cottonseed oil dominated the market. Perrigo, Sun Pharma, Hikma, and Teva are among the current producers. The widespread availability of generics has kept the per-vial cost between $30 and $90 for a 10 mL multidose vial (200 mg/mL) at most U.S. Pharmacies.

How Testosterone Cypionate Works: Mechanism of Action

Testosterone cypionate is a prodrug. It has no androgenic activity until endogenous esterases cleave the cypionate side chain, releasing free testosterone into the circulation. That free testosterone then acts through two primary pathways.

Androgen Receptor Activation

Free testosterone binds the androgen receptor (AR), a nuclear receptor expressed in skeletal muscle, bone, brain, adipose tissue, prostate, and hematopoietic cells. Upon ligand binding, the AR dimerizes, translocates to the nucleus, and activates transcription of androgen-responsive genes governing protein synthesis, erythropoiesis, bone mineral density, and male sexual differentiation.

5-Alpha Reduction and Aromatization

In target tissues like the prostate, skin, and hair follicles, testosterone is converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. DHT binds the androgen receptor with roughly 2 to 3 times greater affinity than testosterone [3]. In adipose tissue and brain, the enzyme aromatase (CYP19A1) converts testosterone to estradiol, which is responsible for bone density maintenance, epiphyseal closure, and aspects of libido and mood regulation in men.

Pharmacokinetics of the Cypionate Ester

After intramuscular injection of testosterone cypionate in cottonseed oil, absorption from the depot site follows a biphasic pattern. Peak serum testosterone levels typically occur 24 to 48 hours post-injection. The terminal half-life is approximately 8 days, though clinical effect duration extends to 10 to 14 days depending on dose and individual metabolism [4].

A 200 mg intramuscular dose produces peak testosterone levels of roughly 1,000 to 1,200 ng/dL, with trough levels falling to 400 to 600 ng/dL by day 7 in most men. This peak-to-trough variation has driven the modern trend toward more frequent, lower-dose protocols (e.g., 80 to 100 mg twice weekly or 50 to 60 mg every 3.5 days) to flatten the pharmacokinetic curve and reduce estradiol spikes.

The Testosterone Trials: A Turning Point in Evidence

For decades, testosterone replacement therapy (TRT) rested on relatively small studies and clinical experience rather than large randomized controlled trials. The Testosterone Trials (TTrials), published in the New England Journal of Medicine in 2016, changed that.

Study Design

The TTrials were a coordinated set of seven double-blind, placebo-controlled trials enrolling 790 men aged 65 years and older with serum testosterone below 275 ng/dL and symptoms of hypogonadism. All participants received testosterone gel (AndroGel 1.62%) rather than cypionate, but the trials established the clinical evidence base for testosterone replacement broadly, including cypionate as the most commonly prescribed injectable formulation in the U.S. [5].

Key Findings

The Sexual Function Trial showed a statistically significant improvement in sexual activity and desire (P<0.001 vs. Placebo). The Physical Function Trial demonstrated a modest increase in 6-minute walking distance. The Vitality Trial found a small but significant improvement in the FACIT-Fatigue score [5].

Later publications from the TTrials reported a statistically significant increase in coronary artery plaque volume (noncalcified plaque) in the testosterone group compared to placebo. However, the clinical significance of this imaging finding remained debated, and the trial was not powered for major adverse cardiovascular events (MACE).

Impact on Prescribing

The TTrials gave prescribers the first rigorous evidence that testosterone replacement improved sexual function and walking distance in older hypogonadal men. Annual testosterone prescriptions in the U.S. Rose from approximately 1.3 million in 2010 to over 3 million by 2013, though the rate of increase had already begun before the TTrials publication, driven by direct-to-consumer advertising and the "Low T" awareness campaigns of 2010 to 2012 [6].

The TRAVERSE Trial and Cardiovascular Safety

The largest randomized cardiovascular safety trial for testosterone, TRAVERSE (N=5,204), published in the New England Journal of Medicine in 2023, randomized men aged 45 to 80 with hypogonadism and preexisting or high risk for cardiovascular disease to testosterone gel or placebo.

Primary Outcome

The primary composite endpoint of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96; 95% CI, 0.78 to 1.17). This met the prespecified criterion for noninferiority [7].

Secondary Signals

TRAVERSE did observe higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group, though these were secondary endpoints and the study was not powered to draw definitive conclusions about them. The Endocrine Society's 2018 clinical practice guideline, published before TRAVERSE, had already recommended against testosterone therapy solely for age-related decline without confirmed hypogonadism (total testosterone consistently below 300 ng/dL on morning samples) [8].

Dr. Shalender Bhasin, principal investigator of TRAVERSE and professor at Harvard Medical School, stated: "TRAVERSE provides reassurance that testosterone replacement therapy in men with hypogonadism and cardiovascular risk factors does not increase the short- to medium-term risk of major adverse cardiovascular events" [7].

Formulation Milestones and Modern Variants

Testosterone cypionate has remained remarkably stable as a formulation since the 1950s. The molecule itself has not changed, but the clinical field around it has evolved.

Subcutaneous Administration

The traditional route for testosterone cypionate is intramuscular (IM) injection into the gluteus, vastus lateralis, or deltoid. Beginning around 2014, clinicians began prescribing subcutaneous (SubQ) injection, typically using 25- to 27-gauge, 5/8-inch insulin syringes. A 2017 study by Olsson et al. Found that subcutaneous testosterone cypionate produced bioequivalent serum testosterone levels compared to intramuscular injection, with reduced injection-site pain and improved patient adherence.

Auto-Injector Devices

Xyosted (testosterone enanthate subcutaneous auto-injector) received FDA approval in 2018, validating the subcutaneous route formally. No cypionate-specific auto-injector has received FDA approval as of May 2026, but the off-label subcutaneous use of standard testosterone cypionate vials with insulin syringes is widely practiced in endocrinology and men's health clinics.

Compounded Formulations

Compounding pharmacies produce testosterone cypionate in alternative carrier oils (grapeseed, sesame) for patients with cottonseed oil allergies. Compounded formulations also come in varying concentrations (100 mg/mL, 200 mg/mL) and combination preparations with anastrozole, though the FDA has warned about quality control variability in compounded products.

Regulatory Evolution: 2014 to Present

The regulatory environment around testosterone cypionate has shifted considerably since 2014.

The 2015 FDA Label Warning

In March 2015, the FDA mandated a Boxed Warning update for all approved testosterone products, cautioning against use in men with age-related testosterone decline (so-called "Low T") rather than confirmed organic hypogonadism. The label revision also added warnings about possible increased risk of heart attack and stroke, reflecting observational studies that predated TRAVERSE [9].

Endocrine Society Guidelines (2018)

The Endocrine Society's 2018 guideline for testosterone therapy in men with hypogonadism recommended:

• Confirming diagnosis with two morning total testosterone levels below 300 ng/dL
• Identifying symptoms consistent with androgen deficiency
• Evaluating for reversible causes (obesity, opioid use, sleep apnea) before initiating therapy
• Monitoring hematocrit, PSA, and testosterone levels at 3 to 6 months and then annually [8]

The guideline specifically listed testosterone cypionate 75 to 100 mg weekly (or 150 to 200 mg every two weeks) as a first-line injectable option.

REMS and Abuse Monitoring

Testosterone products are subject to a class-wide Risk Evaluation and Mitigation Strategy (REMS) focused on the risks of abuse and dependence. The REMS requires a medication guide for patients. The American Urological Association's 2018 guideline echoed these concerns, recommending that clinicians screen for anabolic steroid misuse history before prescribing [10].

Testosterone Cypionate vs. Enanthate: A Historical Divergence

Testosterone cypionate and testosterone enanthate are pharmacokinetically near-identical. The cypionate ester has 8 carbons; the enanthate ester has 7. Their half-lives differ by less than one day. Both dissolve in oil for intramuscular injection.

The geographic split is historical, not pharmacological. Cypionate (Depo-Testosterone) became the dominant formulation in the United States because Upjohn, an American company, marketed it aggressively to U.S. Prescribers in the 1950s and 1960s. Enanthate (Delatestryl) gained dominance in Europe and much of the rest of the world through Schering AG's distribution network [2].

A 2022 systematic review and meta-analysis comparing the two esters found no clinically meaningful differences in serum testosterone levels, symptom improvement, hematocrit elevation, or adverse event rates. The choice between them remains one of availability, cost, and carrier oil preference rather than clinical superiority [11].

Timeline of Key Dates

| Year | Event | |------|-------| | 1935 | Testosterone isolated and synthesized by Butenandt, Ružička, and Laqueur | | 1937 | Testosterone propionate reaches the market | | 1951 | Testosterone cypionate synthesized by Upjohn | | 1979 | FDA approves Depo-Testosterone (NDA 085635) | | 1990 | Anabolic Steroids Control Act classifies testosterone as Schedule III | | 2010 to 2013 | "Low T" advertising campaigns drive prescription volume above 3 million annually | | 2015 | FDA mandates cardiovascular warning on all testosterone product labels | | 2016 | Testosterone Trials (TTrials) published in NEJM | | 2018 | Endocrine Society publishes updated hypogonadism guideline | | 2023 | TRAVERSE trial confirms cardiovascular noninferiority |

What Comes Next for Testosterone Therapy

Several developments may shape the future of testosterone cypionate prescribing. Oral testosterone undecanoate (Jatenzo), approved in 2019, offers an alternative to injections but has not displaced cypionate due to twice-daily dosing requirements and higher cost. Nasal testosterone (Natesto) provides another non-injection option with a very short duration of action (three times daily).

Long-acting testosterone pellets (Testopel) and newer formulations in development aim to reduce injection frequency to every 3 to 6 months. None have matched the cost-effectiveness of generic testosterone cypionate at roughly $3 to $9 per week for most patients.

The Endocrine Society and the American Urological Association are expected to update their testosterone therapy guidelines following the TRAVERSE results. Any revision will likely refine cardiovascular risk stratification and may adjust the threshold for initiating therapy based on the trial's reassuring MACE data [7].

Prescribers initiating testosterone cypionate should obtain two morning total testosterone levels below 300 ng/dL, confirm symptoms of hypogonadism, rule out reversible causes, and check baseline hematocrit and PSA before the first injection [8].